Pulmonx Corp(LUNG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LUNG Pulmonx Corp

Trading 04-16 11:44:04 EDT

1.49

-0.01

-0.67%

High1.60	Low1.44	Vol109.27K
Open1.60	D1 Closing1.50	Amplitude10.67%
Mkt Cap62.93M	Tradable Cap60.24M	Total Shares42.24M
T/O170.35K	T/O Rate0.27%	Tradable Shares40.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LUNG","market":"US","secType":"STK","nameCN":"Pulmonx Corp","latestPrice":1.49,"timestamp":1776354204941,"preClose":1.5,"halted":0,"volume":109272,"delay":0,"changeRate":-0.006666666666666672,"floatShares":40428900,"shares":42237203,"eps":-1.327313,"marketStatus":"Trading","change":-0.01,"latestTime":"04-16 11:44:04 EDT","open":1.6,"high":1.6,"low":1.44,"amount":170348.655588,"amplitude":0.106667,"askPrice":1.49,"askSize":202,"bidPrice":1.48,"bidSize":1204,"shortable":3,"etf":0,"ttmEps":-1.327313,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776369600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1601524800000,"exchange":"NASDAQ","adjPreClose":1.5,"preHourTrading":{"tag":"盘前","latestPrice":1.5697,"preClose":1.5,"latestTime":"09:25 EDT","volume":249,"amount":388.13701679999997,"timestamp":1776345945107,"change":0.0697,"changeRate":0.046467,"amplitude":0.046467},"postHourTrading":{"tag":"盘后","latestPrice":1.5,"preClose":1.5,"latestTime":"19:44 EDT","volume":303,"amount":454.5,"timestamp":1776296656701,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.291053,"impliedVol":0.4734,"impliedVolPercentile":0.072},"requestUrl":"/m/hq/s/LUNG","defaultTab":"news","newsList":[{"id":"2627237234","title":"Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237234","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237234?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:05","pubTimestamp":1776283500,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., April  15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it wil","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/15/3274873/0/en/Pulmonx-to-Report-First-Quarter-2026-Financial-Results-on-April-29-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","LUNG","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625641049","title":"Pulmonx Insiders Forfeit On 14% Gains After Selling Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2625641049","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625641049?lang=en_us&edition=fundamental","pubTime":"2026-04-05 20:02","pubTimestamp":1775390561,"startTime":"0","endTime":"0","summary":"Despite the fact that Pulmonx Corporation (NASDAQ:LUNG) stock rose 14% last week, insiders who sold US$371k worth of...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-lung/pulmonx/news/pulmonx-insiders-forfeit-on-14-gains-after-selling-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-lung/pulmonx/news/pulmonx-insiders-forfeit-on-14-gains-after-selling-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LUNG","BK4082","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618900895","title":"Pulmonx Faces Legal, Regulatory and Financial Risks From Off‑Label Use of Its Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2618900895","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618900895?lang=en_us&edition=fundamental","pubTime":"2026-03-12 14:02","pubTimestamp":1773295327,"startTime":"0","endTime":"0","summary":"Pulmonx Corporation (LUNG) has disclosed a new risk, in the Corporate Activity and Growth category. Pulmonx Corporation faces meaningful exposure i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pulmonx-faces-legal-regulatory-and-financial-risks-from-off‑label-use-of-its-products?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pulmonx-faces-legal-regulatory-and-financial-risks-from-off‑label-use-of-its-products?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4198","LUNG","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617525349","title":"Pulmonx Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2617525349","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617525349?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:28","pubTimestamp":1772720880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LUNG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 05, 2026 09:28 ET (14:28 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","BK4082","LUNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617054993","title":"Pulmonx Secures New Term Loan and Issues Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2617054993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617054993?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:36","pubTimestamp":1772710561,"startTime":"0","endTime":"0","summary":"An update from Pulmonx ( ($LUNG) ) is now available. On March 2, 2026, Pulmonx Corporation entered into a new senior secured term loan facility of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pulmonx-secures-new-term-loan-and-issues-warrants?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pulmonx-secures-new-term-loan-and-issues-warrants?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4198","LUNG","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617560315","title":"Pulmonx Corp reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2617560315","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617560315?lang=en_us&edition=fundamental","pubTime":"2026-03-05 07:34","pubTimestamp":1772667253,"startTime":"0","endTime":"0","summary":"Pulmonx Corp reports results for the quarter ended December 31 - Earnings SummaryPulmonx Corp LUNG.OQ reported a quarterly adjusted loss of 25 cents per share for the quarter ended December 31, higher","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL8N3ZS36I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUNG","BK4198","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617564863","title":"Pulmonx Corporation Publishes Investor Presentation on Zephyr Valve Treatment for Severe Emphysema","url":"https://stock-news.laohu8.com/highlight/detail?id=2617564863","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617564863?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:49","pubTimestamp":1772660949,"startTime":"0","endTime":"0","summary":"Pulmonx Corporation released an investor presentation outlining its focus on treating severe emphysema with the Zephyr Valve, a minimally invasive endobronchial valve designed to reduce hyperinflation by allowing trapped air to escape from a diseased lung lobe while preventing re-entry. The presentation describes the patient selection workflow using the StratX CT-based analysis to identify eligible lobes and the Chartis System to assess collateral ventilation, followed by bronchoscopic valve placement and a minimum three-night hospital stay for monitoring. The company cites evidence from four randomized trials comparing Zephyr Valves with medical management in Chartis-confirmed patients and notes more than 40,000 total patients treated and over 100 scientific publications. It also summarizes reimbursement and coding in the U.S., estimates a global market opportunity of about $12 billion for severe emphysema, and highlights an investigational AeriSeal System intended to expand eligibili","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL5h0sq6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4198","LUNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617561418","title":"Pulmonx sees FY26 revenue $90M-$92M, consensus $94.23M","url":"https://stock-news.laohu8.com/highlight/detail?id=2617561418","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617561418?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:38","pubTimestamp":1772660339,"startTime":"0","endTime":"0","summary":"The company said, “Pulmonx (LUNG) expects revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company expects gros...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pulmonx-sees-fy26-revenue-90m-92m-consensus-94-23m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pulmonx-sees-fy26-revenue-90m-92m-consensus-94-23m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4198","LUNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617569446","title":"Pulmonx Q4 revenue beats expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569446","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569446?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:18","pubTimestamp":1772659108,"startTime":"0","endTime":"0","summary":"Pulmonx Q4 revenue beats expectationsOverviewLung disease treatment firm's Q4 total worldwide revenue fell 5% yr/yr but beat analyst expectationsAdjusted EBITDA loss for Q4 narrowed compared to last y","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL1N3ZS1C3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","LUNG","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617566077","title":"Pulmonx Closes Up to $60 Million Credit Facility With Perceptive Advisors","url":"https://stock-news.laohu8.com/highlight/detail?id=2617566077","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617566077?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:07","pubTimestamp":1772658464,"startTime":"0","endTime":"0","summary":"Pulmonx Corporation has closed a new five-year credit facility of up to $60 million with Perceptive Advisors. The company drew an initial $40 million term loan at closing to refinance existing debt and can access an additional $20 million through the end of 2027 if certain revenue milestones are met. The facility is interest-only until its 2031 maturity and carries interest at one-month Term SOFR, subject to a 3.75% floor, plus 7.0%, with up to 2.0% payable in kind at Pulmonx’s option for three years.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL7J3x5d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4588","IE00B64PRP62.GBP","LU0314104364.USD","BK4198","IE00BKPKM429.USD","LUNG","NDAQ","LU2095319765.USD","SG9999014013.SGD","SG9999014039.USD","BK4112","SG9999014005.SGD","IE00BGHQF748.EUR","BK4082","SG9999014021.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617569860","title":"BRIEF-Pulmonx Q4 EPS USD -0.25","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569860","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569860?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:06","pubTimestamp":1772658405,"startTime":"0","endTime":"0","summary":"Mar 04  - Pulmonx Q4 revenue USD 22.598 million vs. IBES estimate USD 21.7 million.outlook FY revenue USD 90-92 million vs. IBES estimate USD 94.2 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nPLXC3B9EB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4198","LUNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617756603","title":"Pulmonx Q4 Pretax Profit USD -10.239 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617756603","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617756603?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:06","pubTimestamp":1772658360,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nPLXC3B9EB:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","LUNG","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617669569","title":"Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2617669569","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617669569?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:06","pubTimestamp":1772658360,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., March  04, 2026  (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the \"Company\"), a global leader in minimally invasive treatments for lung disease, today rep","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/04/3249737/0/en/Pulmonx-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","LUNG","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616321535","title":"Analysts Are Bullish on Top Healthcare Stocks: Pulmonx (LUNG), Esperion (ESPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616321535","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616321535?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:50","pubTimestamp":1772549413,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pulmonx (LUNG – Research Report), Esperion (ESPR – R...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-pulmonx-lung-esperion-espr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-pulmonx-lung-esperion-espr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","XBI","BK4112","LU0029874061.USD","BK4198","BK4082","BLSX","BK4588","BK4007","BLSG","LABU","LU0128526141.USD","LUNG","ESPR","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616366061","title":"Pulmonx Corp  expected to post a loss of 39 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2616366061","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616366061?lang=en_us&edition=fundamental","pubTime":"2026-03-03 05:12","pubTimestamp":1772485927,"startTime":"0","endTime":"0","summary":"Pulmonx Corp  expected to post a loss of39cents a share - Earnings Preview Pulmonx Corp LUNG.OQ LUNG.O is expected to  show a fall in quarterly revenue when it reports  results on March 4 for the peri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nL8N3ZQ2YB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUNG","BK4198","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612262628","title":"Pulmonx Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2612262628","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612262628?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:16","pubTimestamp":1771593360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LUNG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 20, 2026 08:16 ET (13:16 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUNG","BK4082","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612226782","title":"Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612226782","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612226782?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:00","pubTimestamp":1771592400,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Feb.  20, 2026  (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it wil","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/20/3241894/0/en/Pulmonx-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-March-4-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4198","LUNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590959551","title":"Pulmonx Corporation Files Initial Beneficial Ownership Statement for Chief Science & Technology Officer Srikanth Radhakrishnan","url":"https://stock-news.laohu8.com/highlight/detail?id=2590959551","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590959551?lang=en_us&edition=fundamental","pubTime":"2025-12-11 08:00","pubTimestamp":1765411224,"startTime":"0","endTime":"0","summary":"Pulmonx Corporation Files Initial Beneficial Ownership Statement for Chief Science & Technology Officer Srikanth Radhakrishnan. Pulmonx Corporation has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Srikanth Radhakrishnan, Chief Science & Technology Officer, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmonx Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information cont","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL4PlwV6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Pulmonx Corporation Files Initial Beneficial Ownership Statement for Chief Science & Technology Officer Srikanth Radhakrishnan","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","BK4082","LUNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590272593","title":"Director Daniel P. Florin Reports Sale of Pulmonx Corporation Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590272593","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590272593?lang=en_us&edition=fundamental","pubTime":"2025-12-10 06:59","pubTimestamp":1765321172,"startTime":"0","endTime":"0","summary":"Daniel P. Florin, Director, reported a disposal of common shares of Pulmonx Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmonx Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 09, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL9nFxvP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Daniel P. Florin Reports Sale of Pulmonx Corporation Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUNG","BK4082","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588021428","title":"Pulmonx Grants 1.6 Million Equity Awards to New Executives Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2588021428","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588021428?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:05","pubTimestamp":1764795911,"startTime":"0","endTime":"0","summary":"Pulmonx Corporation has granted equity awards totaling 1,625,000 shares of its common stock to two new executives hired in the fourth quarter of 2025, including Chief Financial Officer and Chief Operating Officer Derrick Sung. As part of his compensation, Mr. Sung received a performance stock unit  award for up to 400,000 shares. The PSUs will vest based on a combination of time-based and performance-based conditions: 33% will vest after one year, with the remainder vesting in equal quarterly installments over the following two years, provided Mr. Sung remains employed. Additionally, vesting is contingent on the company's stock reaching a specified average closing price over a sixty-day period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ad","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLbJYpR3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4588","BK4082","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4585","LU2210150020.SGD","LUNG","BK4198","LU2210149790.SGD","NDAQ","BK4112","LU0314104364.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://pulmonx.com","stockEarnings":[{"period":"1week","weight":0.1628},{"period":"1month","weight":-0.0683},{"period":"3month","weight":-0.1803},{"period":"6month","weight":-0.0132},{"period":"1year","weight":-0.6951},{"period":"ytd","weight":-0.3213}],"compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in Europe, the Middle East, Africa, the Asia-Pacific, the United States, and internationally. Pulmonx Corporation was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.124032},{"month":2,"riseRate":0.666667,"avgChangeRate":0.086482},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.108699},{"month":4,"riseRate":0.5,"avgChangeRate":-0.041411},{"month":5,"riseRate":0.2,"avgChangeRate":-0.130114},{"month":6,"riseRate":0.4,"avgChangeRate":-0.087614},{"month":7,"riseRate":0.6,"avgChangeRate":-0.015052},{"month":8,"riseRate":0.6,"avgChangeRate":-0.034552},{"month":9,"riseRate":0.2,"avgChangeRate":-0.026077},{"month":10,"riseRate":0.4,"avgChangeRate":-0.055336},{"month":11,"riseRate":0.5,"avgChangeRate":-0.058171},{"month":12,"riseRate":0.833333,"avgChangeRate":0.20888}],"exchange":"NASDAQ","name":"Pulmonx Corp","nameEN":"Pulmonx Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pulmonx Corp(LUNG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pulmonx Corp(LUNG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pulmonx Corp,LUNG,Pulmonx Corp股票,Pulmonx Corp股票老虎,Pulmonx Corp股票老虎国际,Pulmonx Corp行情,Pulmonx Corp股票行情,Pulmonx Corp股价,Pulmonx Corp股市,Pulmonx Corp股票价格,Pulmonx Corp股票交易,Pulmonx Corp股票购买,Pulmonx Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pulmonx Corp(LUNG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pulmonx Corp(LUNG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction